Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05900895 · ClinicalTrials.gov registry record · Phase 1
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
A Phase 1 study of Metastatic Breast Cancer, sponsored by Mary D Chamberlin.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT05900895 is a Phase 1 study of Metastatic Breast Cancer that is actively recruiting participants, run by Mary D Chamberlin. The registered enrollment target is 6 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05900895, a Phase 1 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Mary D Chamberlin.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG 17b-estradiol
Study Locations (1)
New Hampshire
- Dartmouth Cancer Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05900895
The ClinicalTrials.gov registry entry for NCT05900895 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Mary D Chamberlin, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT05900895 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05900895 about?
NCT05900895 is a clinical study titled "Estradiol Plus Olaparib for Breast Cancer (PHOEBE)". Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
What is the current status of trial NCT05900895?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2024-07-15. Estimated completion is 2028-12.
What conditions does trial NCT05900895 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT05900895?
The interventions under investigation include: Olaparib (DRUG), 17b-estradiol (DRUG).
Who is sponsoring clinical trial NCT05900895?
This trial is sponsored by Mary D Chamberlin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05900895 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.